Sodium Succinate

CHEMBL1200345 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

162.0 g/mol

LogP

—

Phase

4

Sodium succinate is the sodium salt of succinic acid, a Krebs cycle intermediate used as a pharmaceutical excipient, buffering agent, and in parenteral nutrition formulations to provide a metabolizable organic anion. Succinate is an important cellular energy substrate and signaling molecule, and intravenous formulations have been investigated in conditions including asthma and chronic kidney disease for their potential cytoprotective and anti-inflammatory properties. It is also used as a stabilizer in corticosteroid injectable preparations.

분자량

162.0500 g/mol

TPSA

80.30 Å²

치료 영역

Pain Management Asthma Chronic Obstructive Pulmonary Disease Epilepsy Migraine Infectious Disease Melanoma Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Lymphoma Malaria Heart Failure Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])CCC(=O)O.[Na+]

InChI

InChI=1S/C4H6O4.Na/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+1/p-1

Molecular Formula

C4H4Na2O4

HBD / HBA

- / 4

회전 가능 결합

1

무거운 원자

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Sodium succinate is the sodium salt of succinic acid, a Krebs cycle intermediate used as a pharmaceutical excipient, buffering agent, and in parenteral nutrition formulations to provide a metabolizable organic anion. Succinate is an important cellular energy substrate and signaling molecule, and intravenous formulations have been investigated in conditions including asthma and chronic kidney disease for their potential cytoprotective and anti-inflammatory properties. It is also used as a stabilizer in corticosteroid injectable preparations.

Yes, Sodium Succinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200345. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9020. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Sodium Succinate PillFYI에서

구조

핵심 데이터

분자식: C4H4Na2O4
동의어: 6

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.